Non-adherence to medication specifications is a major cause for poor outcomes in the
therapy of schizophrenia. In situ implantable preparation of aripiprazole, an atypical …

This work was aimed to design and optimize a long acting microsphere-based injectable
formulation of aripiprazole by using D-optimal experimental design methodology …

The main objective of the study is to develop and optimize the potential variables which
influence aripiprazole oral disintegration tablets (ODTs) formulation. Aripiprazole ODTs were …

The current study aims to develop in-situ forming implants (ISFI) of anti-psychotic risperidone
to customize schizophrenia therapy. Non-adherence to treatment is the most prevalent …

Nonadherence to antipsychotic medications for the treatment of schizophrenia is a widely
recognized concern, leading to poorer clinical outcomes and higher treatment costs. Long …

Aripiprazole is considered as a third-generation antipsychotic drug with excellent
therapeutic efficacy in controlling schizophrenia symptoms and was the first atypical anti …

Abstract Background and Objectives Aripiprazole lauroxil (AL), a long-acting injectable
antipsychotic for the treatment of schizophrenia, requires 21 days of oral aripiprazole …

Aripiprazole (ARP) is an antipsychotic drug approved for the treatment of schizophrenia. It is
poorly water-soluble and undergoes extensive hepatic metabolism and P-gp efflux, which …

Self-emulsifying drug delivery systems are a promising approach for the formulation of drug
compounds with poor aqueous solubility. The main objective of this work was to formulate …

The low water solubility of an active pharmaceutical ingredient (aripiprazole) is one of the
most critical challenges in pharmaceutical research and development. This antipsychotic …